Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$3.6B
71M shares
52-week range
$14.79 – $51.06
99% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.73%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $33.0K | $0 | $0 | $0 | $0 | $0 | $263.0K |
| Gross profit | $0 | −$33.0K | $0 | $0 | $0 | $0 | $0 | −$263.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $8.2M | $19.0M | $8.2M | $20.5M | $31.0M | $64.6M | $80.8M | $85.9M |
| Operating income | −$10.7M | −$24.1M | −$9.3M | −$24.8M | −$38.8M | −$83.5M | −$104.6M | −$119.7M |
| EBITDA | −$11.3M | −$23.4M | −$9.3M | −$24.6M | −$37.4M | −$71.3M | −$88.5M | −$103.4M |
| Net income | −$11.3M | −$23.5M | −$19.0M | −$24.7M | −$37.7M | −$71.6M | −$89.0M | −$103.7M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -2.62 | -5.43 | -4.31 | -3.17 | -6.03 | -2.01 | -1.89 | -1.83 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10000 | $-1.77 | $-2.05–$-1.42 | 5 |
| 2027 | $7143 | $-2.40 | $-2.88–$-1.93 | 4 |
| 2028 | $16667 | $-2.98 | $-3.60–$-1.95 | 7 |
| 2029 | $73M | $-2.79 | $-2.79–$-2.79 | 2 |
Forward consensus · source: Financial Modeling Prep
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
www.enliventherapeutics.comNo one on the platform currently holds ELVN.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 59,000 | $1.2M |
No one on the platform has traded ELVN yet.
| $1.4B |
| — |
| NKTRNektar Therapeutics | $63.65 | +2.61% | $1.2B | — |
| ORICORIC Pharmaceuticals, Inc. | $9.53 | +0.74% | $987M | — |
Source: Financial Modeling Prep · peers by sector/industry
$ELVN I really hope for a big dip down to 46-47 to pick back up a few more shares.
View on StockTwits ↗$ELVN Why is sentiment bearish on this stock? Who can possibly be bearish?
View on StockTwits ↗$ELVN they ain’t CHSN. They SKWD. All da way up da Roger ONTO 🐒🍌🧠⏰♾️
View on StockTwits ↗$ELVN Now we just have to avoid that sudden BS dump at the close that we had yesterday. If that happens I am going to start swing-trading a chunk every day.
View on StockTwits ↗$VSTM just a few days away from potentially steamrolling 25% short of the float on data. After getting cut down from $11 to under $4 in 8 months, its time to cover as the smart business practice takes over from here. High risk/high reward here folks. Also watching $EVMN for data any day now, one of Bairds leading candidates for M&A targets this year fwiw. $ELVN has been best in class following TERN before they were taken out. $XBI keep the momentum intact!
View on StockTwits ↗$ELVN Nice movement here, just picked up another 300 shares. on the dip.
View on StockTwits ↗$ALT As much as I love ya'll, I'm seeing someone else. $ELVN is the woman I keep wanting $ALT to be. Half my money is here, half is there. I keep thinking something will happen here, but things ARE happening there.
View on StockTwits ↗Enliven Therapeutics, Inc. ( $ELVN ) SpicyTrade - Daily Stock Analysis https://youtu.be/umrswruzsXo?si=T7kjnnL86gAydsuO
View on StockTwits ↗$ELVN this could catch a few people sleeping
View on StockTwits ↗market warriors $ELVN reversed from open on 5.8x volume - accumulation confirmed, not a squeeze $KLAC late session bid holding near highs follow-through setup tomorrow
View on StockTwits ↗ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development $ELVN $VTI $IWM https://stocktwits.com/news/equity/markets/elvn-stock-on-track-for-best-week-since-march/cZKd3s0R75a
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.